<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20220406054433N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-04-23</date_registration>
      <primary_sponsor>Iran University of Medical Sciences</primary_sponsor>
      <public_title>Effect of common figs and almonds syrup, sweet almond syrup and methylphenidate in the treatment of attention deficit / hyperactivity disorder</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the effectiveness of Persian Medicine products, common figs and almonds syrup, sweet almond syrup and methylphenidate in the treatment of attention deficit / hyperactivity disorder: A randomized double-blind clinical trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-04-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>120</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/62774</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Randomization of patients will be done by randomized blocks using online sealed envelope software and 6 blocks of equal size, and patients will be randomly divided into one of three groups. Groups are identified and coded as A, B, C, and the prescriber and the recipient are unaware of this. Only the coordinator knows who in which group and which group received which treatment, Blinding description: The method of blinding the study will be that the drugs and placebo studied, including Ritalin tablets, sweet almond syrup, almond and fig syrup and ineffective syrup are packed in similar containers. The drug is given to the patient based on randomized sequences. And so the examiner and the patient are blind.</study_design>
      <phase>3</phase>
      <hc_freetext>Attention-deficit hyperactivity disorder.</hc_freetext>
      <i_freetext>Intervention 1: Control group: The first group, they will receive the standard drug methylphenidate (Ritalin) with the dose of 1 mg / kg / day, In the first week (1.2 in the morning, 1.2 in the afternoon) and from the second week onwards (1 in the morning and 1 at noon) and if the patient weighs more than 30 kg, from the second week 3 tablets daily (1 Morning, 1 at noon and 1 at 4 pm). And a simple ineffective syrup as a placebo with the dose of 5 cc, three times a day. The simple syrup is made in the Pharmacy Department of the School of Traditional Medicine, Iran University of Medical Sciences according to British Pharmacopoeia. The duration of use is 12 weeks. Intervention 2: Intervention group: The second group, they will receive the standard drug methylphenidate (Ritalin) with the dose of 1 mg / kg / day, In the first week (1.2 in the morning, 1.2 in the afternoon) and from the second week onwards (1 in the morning and 1 at noon) and if the patient weighs more than 30 kg, from the second week 3 tablets daily (1 Morning, 1 at noon and 1 at 4 pm). And sweet almond syrup at a dose of 5CC three times a day for 12 weeks. Sweet Almond Syrup is a syrup made in the Department of Pharmacy of the School of Persian Medicine, Tehran University of Medical Sciences, which is made of sweet almonds and raisins. This drug is currently available in the pharmaceutical market of Schools of Persian Medicine. Intervention 3: Intervention group: The third group, they will receive the standard drug methylphenidate (Ritalin) with the dose of 1 mg / kg / day, In the first week (1.2 in the morning, 1.2 in the afternoon) and from the second week onwards (1 in the morning and 1 at noon) and if the patient weighs more than 30 kg, from the second week 3 tablets daily (1 Morning, 1 at noon and 1 at 4 pm). And Almond and fig syrup made by NIAK company with registration number 8953162594580741 in the Food and Drug Administration of the Islamic Republic of Iran. This drug is currently available in the pharmaceutical market of Schools of Persian Medicine.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Comparison of quantitative changes before and after the intervention is examined

When:
1 year after the article was published

To whom:
Not planned

Conditions:
Not planned

Where to obtain:
Not planned

How to obtain:
Not planned

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Alireza Mahjoub</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Behesht street, School of traditional medicine</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1114733311</zip>
        <telephone>+98 21 5558 0388</telephone>
        <email>ali_r_mahjoub@yahoo.com</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Hoorieh Mohammadi Kenari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Behesht streer, School of traditional medicine</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1114733311</zip>
        <telephone>+98 21 5558 0388</telephone>
        <email>mohammadikenari.h@iums.ac.ir</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Children 6 to 14 years old suspected to ADHD
Obtain informed consent from the child's parent or guardian
Diagnosis of ADHD by a psychiatrist
New diagnosis of the disorder and not taking another drug</inclusion_criteria>
      <agemin>6 years</agemin>
      <agemax>14 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Mental retardation IQ &lt;70
Simultaneous use of other methods of alternative and complementary medicine
Having medical conditions including cardiovascular disease, gastrointestinal diseases, epilepsy
Having other mental disorders including schizophrenia
Existence of an organic brain problem
Malnutrition and obvious growth disorders
Recent treatment with antipsychotic drugs
Drug dependence or abuse in the last 6 months
History of allergies to sweet almonds and its products
History of allergies to figs and its products
Simultaneous consumption of other products containing almonds (nuts, almond sweets) and figs
The need for behavioral therapy</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>F90.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Attention-deficit hyperactivity disorder, predominantly inattentive type</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Placebo</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Control group: The first group, they will receive the standard drug methylphenidate (Ritalin) with the dose of 1 mg / kg / day, In the first week (1.2 in the morning, 1.2 in the afternoon) and from the second week onwards (1 in the morning and 1 at noon) and if the patient weighs more than 30 kg, from the second week 3 tablets daily (1 Morning, 1 at noon and 1 at 4 pm). And a simple ineffective syrup as a placebo with the dose of 5 cc, three times a day. The simple syrup is made in the Pharmacy Department of the School of Traditional Medicine, Iran University of Medical Sciences according to British Pharmacopoeia. The duration of use is 12 weeks</i_keyword>
      <i_keyword>Intervention group: The second group, they will receive the standard drug methylphenidate (Ritalin) with the dose of 1 mg / kg / day, In the first week (1.2 in the morning, 1.2 in the afternoon) and from the second week onwards (1 in the morning and 1 at noon) and if the patient weighs more than 30 kg, from the second week 3 tablets daily (1 Morning, 1 at noon and 1 at 4 pm). And sweet almond syrup at a dose of 5CC three times a day for 12 weeks. Sweet Almond Syrup is a syrup made in the Department of Pharmacy of the School of Persian Medicine, Tehran University of Medical Sciences, which is made of sweet almonds and raisins. This drug is currently available in the pharmaceutical market of Schools of Persian Medicine.</i_keyword>
      <i_keyword>Intervention group: The third group, they will receive the standard drug methylphenidate (Ritalin) with the dose of 1 mg / kg / day, In the first week (1.2 in the morning, 1.2 in the afternoon) and from the second week onwards (1 in the morning and 1 at noon) and if the patient weighs more than 30 kg, from the second week 3 tablets daily (1 Morning, 1 at noon and 1 at 4 pm). And Almond and fig syrup made by NIAK company with registration number 8953162594580741 in the Food and Drug Administration of the Islamic Republic of Iran. This drug is currently available in the pharmaceutical market of Schools of Persian Medicine.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Severity of attention deficit / hyperactivity disorder based on the questionnaire score. Timepoint: At the beginning of the study (before the intervention), 4, 8 and 12 weeks after starting the drug. Method of measurement: Teacher and Parent ADHD rating scale.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Evaluation of drug side effects. Timepoint: Once every 2 weeks after starting treatment. Method of measurement: Checklist of drug side effects and possible side effects based on CTCAE criteria (Common Terminology Criteria for Adverse Events v4.03, 2010).</sec_outcome>
      <sec_outcome>BMI, and clinical examination results. Timepoint: 4, 8 and 12 weeks after the start of the intervention. Method of measurement: questionnaire.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Iran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-03-16</approval_date>
        <contact_name>Research Ethics Committees of Iran University of Medical Sciences</contact_name>
        <contact_address>5th floor, Headquarters Building, Iran University of Medical Sciences, Hemmat Highway next to Milad Tower Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
